RapidARC IMRT vs conventional IMRT

New Topic Post Reply Printable Version
[ << Previous Thread | Next Thread >> ]

Squirm
Veteran Member


Date Joined Sep 2008
Total Posts : 744
   Posted 8/26/2009 5:47 PM (GMT -6)   
I was wondering if anyone has had radiation treatment with RapidARC IMRT/IGRT.

Post Edited (Squirm) : 8/26/2009 5:06:49 PM (GMT-6)


livinadream
Veteran Member


Date Joined Apr 2008
Total Posts : 1382
   Posted 8/26/2009 8:10 PM (GMT -6)   
I am not familiar with that. I had IMRT and I suppose it was conventional. I will watch what others post.

peace to you
dale
My PSA at diagnosis was 16.3
age 47 (current)

http://www.caringbridge.org/visit/dalechildress

My gleason score from prostate was 4+5=9 and from the lymph nodes (3 positive) was 4+4=8
I had 44 IMRT's
Casodex
Currently on Lupron
I go to The Cancer Treatment Center of America
Married with two kids
latest PSA 5-27-08 0.11

PSA July 24th, 2008 is 0.04
PSA Dec 16th, 2008 is .016
PSA Mar 30th, 2009 is .02
PSA July 28th 2009 is .01

Testosterone keeps rising, the current number is 156, up from 57 in May

T level dropped to 37 Mar 30th, 2009
cancer in 4 of 6 cores
92%
80%
37%
28%


geezer99
Veteran Member


Date Joined Apr 2009
Total Posts : 990
   Posted 8/26/2009 8:51 PM (GMT -6)   
RapidARC is a brand name for a radiation machine. You can read what the manufacturer says here:
www.varian.com/us/oncology/treatments/treatment_techniques/rapidarc/
It is hard to tell if this is a treatment breakthrough or just product puffery.
Here is an abstreact from a medical journal

RapidArc volumetric modulated therapy planning for prostate cancer patients
Authors: Flemming Kjaeligr-Kristoffersen a; Lars Ohlhues a; Joakim Medin a; Stine Korreman a
Affiliation: a Department of Radiation Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark
DOI: 10.1080/02841860802266748
Publication Frequency: 8 issues per year
Published in: journal Acta Oncologica, Volume 48, Issue 2 February 2009 , pages 227 - 232
First Published: February 2009
Subject: Oncology;

Abstract
Purpose. Recently, Varian Medical Systems have announced the introduction of a new treatment technique, RapidArc, in which dose is delivered over a single gantry rotation with dynamically variable MLC positions, dose rate and gantry speed. At Rigshospitalet, the RapidArc technique was brought into clinical practice in May 2008 for treatment of prostate cancer patients. We report here our experiences with performing treatment planning using the Eclipse RapidArc optimization software for this patient group. Material and methods. A stand-alone installation of Eclipse 8.5 with RapidArc optimization capability was performed at Rigshospitalet. Patient data for 8 prostate cancer patients were imported, most of whom were previously treated at Rigshospitalet using IMRT. Three of the patients were treated at Rigshospitalet using the RapidArc technique. Treatment plans were optimized using objectives as given by standard guidelines for clinical treatment planning. RapidArc plans were compared to the IMRT plans by which the patients were actually treated or in the three cases treated with the RapidArc technique to IMRT plans achieved using standard guidelines. Comparison was done with respect to target coverage, doses to rectum and bladder, over-all maximum dose and number of monitor units. Results. Overall, the RapidArc treatment plans gave better or equal sparing of the organs at risk than the IMRT treatment plans. The number of monitor units was lower in most cases, by up to approximately 75%. However, the target dose homogeneity was not as high as for IMRT. The low-dose bath was larger than for IMRT. Conclusion. RapidArc optimization is very promising, especially regarding the potential of reducing the number of monitor units, while providing good sparing of organs at risk. Some improvement is still warranted with respect to achieving high target dose homogeneity.
Age at diagnosis 66, PSA 5.5
Biopsy 12/08 12 cores, 8 positive
Gleason 3+4=7
CAT scan, Bone scan 1/09 both negative.

Robotic surgery 03/03/09 Catheter Out 03/08/09
Pathology: Lymph nodes & Seminal vesicles negative
Margins positive, Capsular penetration extensive Gleason 4+3=7
6 weeks: 1 pad/day, 1 pad/night -- mostly dry at night.
10 weeks: no pad at night -- slight leakage day/1 pad.
3 mo. PSA 0.0 - now light pads

Post Edited (geezer99) : 8/26/2009 7:59:06 PM (GMT-6)


Purgatory
Elite Member


Date Joined Oct 2008
Total Posts : 25393
   Posted 8/26/2009 9:12 PM (GMT -6)   
good info geezer, i had never heard of it either.
 Age 57, 56 at DX, PSA 7/7 5.8, 7/8 12.3,9/8 14.5
3rd Biopsy Sept 08: Positive 7 of 7 cores, 40-90%, Gleason 7, 4+3
Open RP surgery 11/14/8, Right nerves spared, 4 days hospital, staples out 11/24/8, 5th cath out on 1/19/9
 Pathlogy Report:Gleason 3+4=7, pT2c, 42 grm, tumor 20%, Contained in capsule, one post. margin, clear lymph nodes 
2009 PSA   2/9 .05, 5/9 .10, 6/9 .11, 8/9 .16
Lastest 7/13 met with Rad. Oncl, considering options, 7/20 Catheter #6 after complete blockage, 8/14 met with Rad Oncl, 8/18 - laser scope surgery to clear blockage, now on Cath #7, 8/26 - cath removed
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Geebra
Regular Member


Date Joined May 2009
Total Posts : 476
   Posted 8/26/2009 10:05 PM (GMT -6)   
Our local radiation center has a similar machine called TomoTherapy. The advantages are in faster delivery. The disadvantages are doze homogeneity. MSK is considering buying RapidArc. My radiation doc there told me I don't need it, but it may have advantages for head and neck cancers because it allows better preservation of healthy tissue. The treatment center gains efficiency as more pations could be treated on the same machine.

Father died from poorly differentiated PCa @ 78 - normal PSA and DRE

5 biopsies over 4 years negative while PSA going from 3.8 to 28

Dx Nov 2007, age 46, PSA 29, Gleason 4+4=8

Decided to participate in clinical trial at Duke - 6 rounds of chemo (Taxotere+Avastin)

PSA prior to treatment on 1/8/2008 is 33.90, bounced on 1/31/2008 to 38.20, and down at the end of the treatment (4/24/2008) to 20.60

RRP at Duke (Dr. Moul) on 6/16/2008, Gleason downgraded 4+3=7, T3a N0MX, focal extraprostatic extension, two small positive margins

PSA undetectable for 8 months, then 2/6/2009-0.10, 4/26/2009-0.17, 5/22/2009-0.20, 6/11/2009-0.27

Salvage IMRT + 6 Months ADT: Casodex started 6/12/2009, Lupron 6/22/2009, PSA 6/25/2009-0.1, T=516, 7/23/2009-<0.05, T<10, IMRT to start mid-Aug


Squirm
Veteran Member


Date Joined Sep 2008
Total Posts : 744
   Posted 8/27/2009 9:55 AM (GMT -6)   
Also with RapidARC the process is quicker, therefore less chance of patient movement and less collateral damage.
New Topic Post Reply Printable Version
Forum Information
Currently it is Friday, September 21, 2018 5:15 AM (GMT -6)
There are a total of 3,005,379 posts in 329,237 threads.
View Active Threads


Who's Online
This forum has 161774 registered members. Please welcome our newest member, Audreyli.
216 Guest(s), 5 Registered Member(s) are currently online.  Details
Deep_sleep, JOKERWILD477, Mike0228, fiddlecanoe, Worried Guy